Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus

Pediatric Infectious Disease Journal

Volumn 15, Issue 12, 1996, Pages 1082-1086

  Güris, Dalya ^a   Mccready, Jill ^c   Watson, John C ^a   Atkinson, William L ^a   Heath, Janet L ^b   Bellini, William J ^b   Polloi, Anthony ^c  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c Bureau of Public Health   (Palau)

Author keywords

duration of vaccine induced immunity; immunization; Measles; measles vaccine; Micronesia; outbreak; Palau; vaccine effectiveness

Indexed keywords

MEASLES VACCINE;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HOST RESISTANCE; HUMAN; IMMUNE STATUS; MAJOR CLINICAL STUDY; MEASLES; MEASLES VACCINATION; PALAU; PRIORITY JOURNAL;

CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; HUMANS; IMMUNITY; IMMUNIZATION, SECONDARY; MEASLES; MEASLES VACCINE; PALAU; RISK FACTORS; SAMPLING STUDIES; TIME FACTORS;

EID: 0030457358     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199612000-00005     Document Type: Article

References (20)

1. Panum LP. Observations made during the epidemic of measles on the Faroe Islands in the year 1846. Baltimore: Williams & Wilkins, 1938-1939.
2. Centers for Disease Control. Measles prevention: recommendations of the Immunization Practices Advisory Committee (ACIP): MMWR 1989;38(n.S9):1-13.
3. Markowitz LE, Preblud SR, Fine PEM, Orenstein WA. Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J 1990;9:101-10.
4. Mathias RG, Meekison WG, Arcand TA, Schechter MT. The role of secondary vaccine failures in measles outbreaks. Am J Public Health 1989;79:475-8.
5. Gary D, Skarvall H. B-cell memory is short-lived in the absence of antigen. Nature 1988;336:70-3.
6. McIntyre RC, Preblud SR, Polloi A, Korean M. Measles and measles vaccine efficacy in a remote island population. Bull WHO 1982;60:767-75.
7. Hummel KB, Erdman DD, Heath J, Bellini WJ. Baculovirus expression of the nucleoprotein gene of measles virus and utility of the recombinant protein in diagnostic enzyme immunoassays. J Clin Microbiol 1992;30:2874-80.
8. Orenstein WA, Bender RH, Hinman AR. Assessing vaccine efficacy in the field. Epidemiol Rev 1988;10:212-41.
9. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: Wiley, 1981.
10. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985;41:55-68.
11. King GE, Markowitz LE, Patriarca PA, Dales LG. Clinical efficacy of measles vaccine during the 1990 measles epidemic. Pediatr Infect Dis J 1991;10:883-8.
12. Brown P, Gajdusek DC, Tsai T. Persistence of measles antibody in the absence of circulating natural virus five years after immunization of an isolated virgin population with Edmonston B vaccine. Am J Epidemiol 1969;90:514-8.
13. Black PL, Gudnadottir M. Measles vaccination in Iceland: Three-year follow-up of antibody titres in adults and children. Bull WHO 1966;35:955-7.
14. Pedersen IR, Mordhorst CH, Ewald T, von Magnus H. Long-term antibody response after measles vaccination in an isolated Arctic society in Greenland. Vaccine 1986;4:173-8.
15. Watson JC, Pearson JA, Markowitz LE, et al. An evaluation of measles revaccination among school-entry-aged children. Pediatrics 1996;97:613-8.
16. Nkowane BM, Bart SW, Orenstein WA, Baltier M. Measles outbreak in a vaccinated school population: epidemiology, chains of transmission and the role of vaccine failures. Am J Public Health 1987;77:434-8.
17. Hutchins SS, Markowitz LE, Mead P, et al. A school-based measles outbreak: the effect of a selective revaccination policy and risk factors for vaccine failure. Am J Epidemiol 1990;132:157-68.
18. Robertson SE, Markowitz LE, Berry DA, Dini EF, Orenstein WA. A million dollar measles outbreak: epidemiology, risk factors, and a selective revaccination strategy. Public Health Rep 1992;107:24-31.
19. Christenson B, Bottiger M. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine 1994;12:129-33.
20. Markowitz LE, Katz SL. Measles vaccine. In: Plotkin SA, Mortimer EA, eds. Vaccines. 2nd ed. Philadelphia: Saunders, 1994:229-76.